Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

PROOF OF CONCEPT STUDY ON THE EFFICACY OF INHALATORY TARGETED IMATINIB NANOFORMULATIONS IN PULMONARY HYPERTENSION AND POST-INFLAMMATORY FIBROSIS.

NCT06917196 is registered in ClinicalTrials.gov with Fondazione IRCCS Policlinico San Matteo di Pavia as lead sponsor.

NCT NCT06917196
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06917196 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
PROOF OF CONCEPT STUDY ON THE EFFICACY OF INHALATORY TARGETED IMATINIB NANOFORMULATIONS IN PULMONARY HYPERTENSION AND POST-INFLAMMATORY FIBROSIS.
Lead sponsor
Fondazione IRCCS Policlinico San Matteo di Pavia
Phase
Observational
Overall status
Recruiting
Start date
December 4, 2023
Completion date
June 4, 2026
Enrollment
16 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lung fibrosis interstitial, pulmonary arterial hypertension (pah)